Skip to main content

Monoclonal Antibody Targets, Kills Leukemia Cells

Monoclonal Antibody Targets, Kills Leukemia Cells

 Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells
The findings, published in the online Early Edition of the Proceedings of the National Academy of Sciences on March 25, 2013 represent a potential new therapy for treating at least some patients with CLL, the most common type of blood cancer in the United States.
CLL cells express high levels of a cell-surface glycoprotein receptor called CD44. Principal investigator Thomas Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research, and colleagues identified a monoclonal antibody called RG7356 that specifically targeted CD44 and was directly toxic to cancer cells, but had little effect on normal B cells.
Moreover, they found RG7356 induced CLL cells that expressed the protein ZAP-70 to undergo apoptosis or programmed cell death. Roughly half of CLL patients have leukemia cells that express ZAP-70. Such patients typically have a more aggressive form of the disease than patients with CLL cells that do not express that specific protein.

Previous research by Kipps and others has shown that CLL cells routinely undergo spontaneous or drug-induced cell death when removed from the body and cultured in the laboratory. They found that CLL cells receive survival signals from surrounding non-tumor cells that are present in the lymph nodes and bone marrow of patients with CLL. One of these survival signals appears to be transmitted through CD44. However, when CD44 is bound by the RG7356 monoclonal antibody, it seems to instead convey a death signal to the leukemia cell.
"By targeting CD44, it may be possible to kill CLL cells regardless of whether there are sufficient numbers of so-called 'effector cells,' which ordinarily are required by other monoclonal antibodies to kill tumor cells," said Kipps. "We plan to initiate clinical trials using this humanized anti-CD44 monoclonal antibody in the not-too-distant future."
Co-authors were Suping Zhang, Christina C.N. Wu, Jessie-Farah Fecteau, Bing Cui, Liguang Chen, Ling Zhang, Rongrong Wu, Laura Rassenti, and Fitzgerald S. Lao, Department of Medicine, UCSD Moores Cancer Center; and Stefan Weigand, Roche Diagnostics GmbH, Germany.
Funding for this study came, in part, from the National Institutes of Health (grant PO1-CA081534) and the UC San Diego Moores Cancer Blood Center Research Fund.

Story Source:
The above story is reprinted from materials provided by University of California, San Diego Health Sciences.

Journal Reference:
  1. Suping Zhang, Christina C. N. Wu, Jessie-F. Fecteau, Bing Cui, Liguang Chen, Ling Zhang, Rongrong Wu, Laura Rassenti, Fitzgerald Lao, Stefan Weigand, and Thomas J. Kipps. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. PNAS, March 25, 2013 DOI: 10.1073/pnas.1221841110

Comments

Caspase 3 antibody said…
Thank you for the article.
April 12, 2013 at 10:33 AM
Post a Comment

Popular posts from this blog

Exercise and proper sleep can reduce cancer risk

The latest research shows that proper exercise which should be regulated ( Like 30mins daily ) and proper sleep can reduce cancer risks. Because, daily exercise maintains body metabolism in a steady way and this prevents altered metabolism within our body. Also, proper sleep which should be at least 6 hours at night can reduces the altered endocrine and metabolic functions. So, proper sleep is very important. This all can reduce cancer risks upto 55%.
Post a Comment
Read more

Treatment with stem cells, a new era in medical science.......

A new Era is coming forward in the treatment of human body. That is the STEM CELL THERAPY. If this treatment comes forward then medical science can treat many of those major diseases that are killing a large number of people each year. There are many diseases now that can't be cured by medical treatment, like Paralysis . If a patient has paralysis then doctors give him only some supportive treatment to improve his nerve supply on that affected area. But it can't give a redical cure. Because if a nerve cell damaged it cant be regenerated due to it is mane if stable cells. But, if a stem cell is replaced on that area then it can regenerate a nerve cell because stem cell can grow in the form of any cells or tissues, it has that capacity. Although a stem cell can grow in any form of a tissue or an organ. So, if we can place a stem cell in that affected hand or leg then this stem cell will grow under control and can regenerate into that original tissue. So, the patient will be cu...
Post a Comment
Read more

Artificial pancreas ... an option

Coming Soon: 'Artificial Pancreas' Options for Diabetes Miriam E Tucker June 20, 2016   NEW ORLEANS — Nearly closed-loop systems (also referred to as an "artificial pancreas") for improving glycemic control and minimizing hypoglycemia in type 1 diabetes are advancing rapidly, including iterations that deliver insulin alone, insulin with glucagon, or glucagon alone. Findings for several of the products in development demonstrating improvements in glycemic control and reductions in hypoglycemia were presented here at the  American Diabetes Association (ADA) 2016 Scientific Sessions . "Some people may do well on insulin only, while others may need glucagon," Vincent Crabtree, PhD, director of the artificial pancreas program at JDRF, in New York, told  Medscape Medical News , adding, "JDRF would like people to have choice, and we'd like all to be covered [by payers]." The insulin-only hybrid closed-loop 670G system (Medtronic MiniMed) is the...
Post a Comment
Read more